p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy

Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy

(2015)   Oncotarget

Stapled Peptides with Improved Potency and Specificity That Activate p53

(2012) Christopher J. Brown et al.   ACS Chemical Biology

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells

(2012) Ingeborg M.M. van Leeuwen et al.   CELL CYCLE

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy

(2010) Meng Ling Choong et al.   CELL CYCLE

Regulation of nucleolar signalling to p53 through NEDDylation of L11

(2009) Anders Sundqvist et al.   EMBO REPORTS

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

(2009) S. Sur et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

(2008) O. Gluz et al.   ANNALS OF ONCOLOGY